Literature DB >> 28368484

High Glucose Variability Increases Mortality Risk in Hospitalized Patients.

Amit Akirov1,2, Talia Diker-Cohen1,3, Hiba Masri-Iraqi1,2, Ilan Shimon1,2.   

Abstract

Context: Glucose variability (GV) is common among hospitalized patients, but the prognostic implications are not understood. Objective: Investigate the association between GV, hospital length of stay (LOS), and mortality.
Methods: GV was assessed by coefficient of variance (CV) and standard deviation (SD) of glucose values during hospitalization. Setting: Historical prospectively collected data of patients hospitalized between January 2011 and December 2013. Patients: Patients ≥18 years old. Main outcome: LOS, and in-hospital and mortality at end of follow-up.
Results: The cohort included 20,303 patients (mean age ± SD, 70 ± 17 years; 51% men; median follow-up, 1022 days), of whom 8565 patients (42%) had diabetes mellitus (DM). Mean LOS was longer with higher CV or SD tertiles in patients without and with DM. In-hospital mortality was 8.2%, associated with higher tertiles of CV (4%, 10%, 19%) and SD (4%, 11%, 21%) in patients without DM and with DM (3%, 5%, 10%; and 2%, 4%, 9%, respectively). Mortality at the end of follow-up was increased in patients without DM with higher CV (28%, 42%, 55%) and SD (28%, 44%, 57%) tertiles and in patients with DM (26%, 35%, 45%; and 25%, 34%, 44%, respectively). Multivariate analysis indicated increased risk for in-hospital and end of follow-up mortality, in both groups. Adjustment for glucocorticoid treatment or hypoglycemia did not affect the results. Glucose levels during hospitalization and GV were two independent factors affecting LOS and in-hospital mortality. In each CV tertile, mortality was higher with median glucose ≥180 mg/dL, compared with <180 mg/dL. Conclusions: In hospitalized patients with and without DM, increased GV is associated with longer hospitalization and increased short- and long-term mortality.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28368484     DOI: 10.1210/jc.2017-00450

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Impact of acute-phase insulin secretion on glycemic variability in insulin-treated patients with type 2 diabetes.

Authors:  Yiming Si; Yun Shen; Jingyi Lu; Xiaojing Ma; Lei Zhang; Yifei Mo; Wei Lu; Wei Zhu; Yuqian Bao; Gang Hu; Jian Zhou
Journal:  Endocrine       Date:  2020-01-31       Impact factor: 3.633

Review 2.  Glycemic variability: adverse clinical outcomes and how to improve it?

Authors:  Zheng Zhou; Bao Sun; Shiqiong Huang; Chunsheng Zhu; Meng Bian
Journal:  Cardiovasc Diabetol       Date:  2020-07-04       Impact factor: 9.951

Review 3.  Effects of Cardiovascular Risk Factor Variability on Health Outcomes.

Authors:  Seung-Hwan Lee; Mee Kyoung Kim; Eun-Jung Rhee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

4.  Association of fasting plasma glucose variability with gestational diabetes mellitus: a nationwide population-based cohort study.

Authors:  Jung A Kim; Jinsil Kim; Eun Roh; So-Hyeon Hong; You-Bin Lee; Sei Hyun Baik; Kyung Mook Choi; Eunjin Noh; Soon Young Hwang; Geum Joon Cho; Hye Jin Yoo
Journal:  BMJ Open Diabetes Res Care       Date:  2020-04

5.  Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients.

Authors:  Nobutoshi Fushimi; Takashi Shibuya; Yohei Yoshida; Shun Ito; Hiroki Hachiya; Akihiro Mori
Journal:  J Diabetes Investig       Date:  2019-06-28       Impact factor: 4.232

6.  Fructosamine is a valuable marker for glycemic control and predicting adverse outcomes following total hip arthroplasty: a prospective multi-institutional investigation.

Authors:  Noam Shohat; Karan Goswami; Leigham Breckenridge; Michael B Held; Arthur L Malkani; Roshan P Shah; Ran Schwarzkopf; Javad Parvizi
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.379

7.  Fasting glucose variability in young adulthood and incident diabetes, cardiovascular disease and all-cause mortality.

Authors:  Michael P Bancks; April P Carson; Cora E Lewis; Erica P Gunderson; Jared P Reis; Pamela J Schreiner; Yuichiro Yano; Mercedes R Carnethon
Journal:  Diabetologia       Date:  2019-05-22       Impact factor: 10.122

8.  Greater daily glucose variability and lower time in range assessed with continuous glucose monitoring are associated with greater aortic stiffness: The Maastricht Study.

Authors:  Yuri D Foreman; William P T M van Doorn; Nicolaas C Schaper; Marleen M J van Greevenbroek; Carla J H van der Kallen; Ronald M A Henry; Annemarie Koster; Simone J P M Eussen; Anke Wesselius; Koen D Reesink; Miranda T Schram; Pieter C Dagnelie; Abraham A Kroon; Martijn C G J Brouwers; Coen D A Stehouwer
Journal:  Diabetologia       Date:  2021-05-15       Impact factor: 10.122

9.  Association of glucose variability at the last day of hospitalization with 30-day readmission in adults with diabetes.

Authors:  Elias K Spanakis; Lakshmi G Singh; Tariq Siddiqui; John D Sorkin; George Notas; Michelle F Magee; Jeffrey C Fink; Min Zhan; Guillermo E Umpierrez
Journal:  BMJ Open Diabetes Res Care       Date:  2020-05

10.  Reducing Inpatient Hypoglycemia in the General Wards Using Real-time Continuous Glucose Monitoring: The Glucose Telemetry System, a Randomized Clinical Trial.

Authors:  Lakshmi G Singh; Medha Satyarengga; Isabel Marcano; William H Scott; Lillian F Pinault; Zhaoyong Feng; John D Sorkin; Guillermo E Umpierrez; Elias K Spanakis
Journal:  Diabetes Care       Date:  2020-08-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.